ID   MPRF_STAA8              Reviewed;         840 AA.
AC   Q2G2M2;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   21-MAR-2006, sequence version 1.
DT   29-SEP-2021, entry version 100.
DE   RecName: Full=Phosphatidylglycerol lysyltransferase;
DE            EC=2.3.2.3;
DE   AltName: Full=Lysylphosphatidylglycerol synthase;
DE            Short=LPG synthase;
DE   AltName: Full=Multiple peptide resistance factor;
GN   Name=mprF; OrderedLocusNames=SAOUHSC_01359;
OS   Staphylococcus aureus (strain NCTC 8325 / PS 47).
OC   Bacteria; Firmicutes; Bacilli; Bacillales; Staphylococcaceae;
OC   Staphylococcus.
OX   NCBI_TaxID=93061;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], DISRUPTION PHENOTYPE, AND HOST DEFENSE
RP   PEPTIDES RESISTANCE.
RX   PubMed=11342591; DOI=10.1084/jem.193.9.1067;
RA   Peschel A., Jack R.W., Otto M., Collins L.V., Staubitz P., Nicholson G.,
RA   Kalbacher H., Nieuwenhuizen W.F., Jung G., Tarkowski A., van Kessel K.P.M.,
RA   van Strijp J.A.G.;
RT   "Staphylococcus aureus resistance to human defensins and evasion of
RT   neutrophil killing via the novel virulence factor MprF is based on
RT   modification of membrane lipids with L-lysine.";
RL   J. Exp. Med. 193:1067-1076(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=NCTC 8325 / PS 47;
RA   Gillaspy A.F., Worrell V., Orvis J., Roe B.A., Dyer D.W., Iandolo J.J.;
RT   "The Staphylococcus aureus NCTC 8325 genome.";
RL   (In) Fischetti V., Novick R., Ferretti J., Portnoy D., Rood J. (eds.);
RL   Gram positive pathogens, 2nd edition, pp.381-412, ASM Press, Washington
RL   D.C. (2006).
RN   [3]
RP   HOST DEFENSE PEPTIDES RESISTANCE.
RX   PubMed=12496209; DOI=10.1128/iai.71.1.546-549.2003;
RA   Kristian S.A., Duerr M., van Strijp J.A.G., Neumeister B., Peschel A.;
RT   "MprF-mediated lysinylation of phospholipids in Staphylococcus aureus leads
RT   to protection against oxygen-independent neutrophil killing.";
RL   Infect. Immun. 71:546-549(2003).
RN   [4]
RP   FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=14769468; DOI=10.1016/s0378-1097(03)00921-2;
RA   Staubitz P., Neumann H., Schneider T., Wiedemann I., Peschel A.;
RT   "MprF-mediated biosynthesis of lysylphosphatidylglycerol, an important
RT   determinant in staphylococcal defensin resistance.";
RL   FEMS Microbiol. Lett. 231:67-71(2004).
RN   [5]
RP   FUNCTION, KINETIC PARAMETERS, SUBCELLULAR LOCATION, AND DISRUPTION
RP   PHENOTYPE.
RX   PubMed=14702396; DOI=10.1099/mic.0.26706-0;
RA   Oku Y., Kurokawa K., Ichihashi N., Sekimizu K.;
RT   "Characterization of the Staphylococcus aureus mprF gene, involved in
RT   lysinylation of phosphatidylglycerol.";
RL   Microbiology 150:45-51(2004).
CC   -!- FUNCTION: Catalyzes the transfer of a lysyl group from L-lysyl-
CC       tRNA(Lys) to membrane-bound phosphatidylglycerol (PG), which produces
CC       lysylphosphatidylglycerol (LPG), a major component of the bacterial
CC       membrane with a positive net charge. LPG synthesis contributes to
CC       bacterial virulence as it is involved in the resistance mechanism
CC       against cationic antimicrobial peptides (CAMP) produces by the host's
CC       immune system (defensins, cathelicidins) and by the competing
CC       microorganisms (bacteriocins). In fact, the modification of anionic
CC       phosphatidylglycerol with positively charged L-lysine results in
CC       repulsion of the peptides. Consequently, MprF is shown to affect
CC       resistance and susceptibility to moenomycin and vancomycin, resistance
CC       to human defensins (HNP1-3) and evasion of oxygen-independent
CC       neutrophil killing and susceptibility to methicillin, oxacillin,
CC       bacitracin, gentamicin, beta-lactams and synthetic peptides (hBD3,
CC       CAP18) and other cationic antimicrobial peptides.
CC       {ECO:0000269|PubMed:14702396, ECO:0000269|PubMed:14769468}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) + L-lysyl-
CC         tRNA(Lys) = 1,2-diacyl-sn-glycero-3-phospho-1'-(3'-O-L-lysyl)-sn-
CC         glycerol + tRNA(Lys); Xref=Rhea:RHEA:10668, Rhea:RHEA-COMP:9696,
CC         Rhea:RHEA-COMP:9697, ChEBI:CHEBI:64716, ChEBI:CHEBI:75792,
CC         ChEBI:CHEBI:78442, ChEBI:CHEBI:78529; EC=2.3.2.3;
CC         Evidence={ECO:0000269|PubMed:14769468};
CC   -!- ACTIVITY REGULATION: Inhibited by cadaverin or RNase A.
CC       {ECO:0000269|PubMed:14769468}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=6.9 uM for L-lysyl-tRNA {ECO:0000269|PubMed:14702396};
CC         KM=56 uM for phosphatidylglycerol {ECO:0000269|PubMed:14702396};
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:14702396};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:14702396}.
CC   -!- DISRUPTION PHENOTYPE: Strains lacking this gene do not have a
CC       detectable amount of LPG in their membrane lipids. They are also more
CC       susceptible to defensin and have a higher affinity for cationic
CC       peptides. {ECO:0000269|PubMed:11342591, ECO:0000269|PubMed:14702396}.
CC   -!- SIMILARITY: Belongs to the LPG synthase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF145699; AAK58115.1; -; Genomic_DNA.
DR   EMBL; CP000253; ABD30454.1; -; Genomic_DNA.
DR   RefSeq; WP_001071135.1; NZ_LS483365.1.
DR   RefSeq; YP_499886.1; NC_007795.1.
DR   STRING; 1280.SAXN108_1376; -.
DR   EnsemblBacteria; ABD30454; ABD30454; SAOUHSC_01359.
DR   GeneID; 3920064; -.
DR   KEGG; sao:SAOUHSC_01359; -.
DR   PATRIC; fig|93061.5.peg.1243; -.
DR   eggNOG; COG0392; Bacteria.
DR   eggNOG; COG2898; Bacteria.
DR   HOGENOM; CLU_008255_7_1_9; -.
DR   OMA; WEPRYMA; -.
DR   BioCyc; MetaCyc:MONOMER-7721; -.
DR   BRENDA; 2.3.2.3; 3352.
DR   PHI-base; PHI:7738; -.
DR   PRO; PR:Q2G2M2; -.
DR   Proteomes; UP000008816; Chromosome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016755; F:aminoacyltransferase activity; IBA:GO_Central.
DR   GO; GO:0050071; F:lysyltransferase activity; IEA:UniProtKB-EC.
DR   GO; GO:0006629; P:lipid metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0055091; P:phospholipid homeostasis; IBA:GO_Central.
DR   GO; GO:0046677; P:response to antibiotic; IEA:UniProtKB-KW.
DR   InterPro; IPR016181; Acyl_CoA_acyltransferase.
DR   InterPro; IPR022791; L-PG_synthase/AglD.
DR   InterPro; IPR024320; LPG_synthase_C.
DR   Pfam; PF09924; DUF2156; 1.
DR   Pfam; PF03706; LPG_synthase_TM; 1.
DR   SUPFAM; SSF55729; SSF55729; 1.
DR   TIGRFAMs; TIGR00374; TIGR00374; 1.
PE   1: Evidence at protein level;
KW   Antibiotic resistance; Cell membrane; Lipid metabolism; Membrane;
KW   Reference proteome; Transferase; Transmembrane; Transmembrane helix;
KW   Virulence.
FT   CHAIN           1..840
FT                   /note="Phosphatidylglycerol lysyltransferase"
FT                   /id="PRO_0000247953"
FT   TOPO_DOM        1..8
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        9..29
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        30..52
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        53..73
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        74..89
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        90..110
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        111..128
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        129..149
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        150..161
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        162..182
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        183..200
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        201..221
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        222..229
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        230..250
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        251..271
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        272..292
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        293..337
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        338..358
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        359..369
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        370..390
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        391..394
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        395..415
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        416..436
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        437..450
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        451..471
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        472..489
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        490..510
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        511..840
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
SQ   SEQUENCE   840 AA;  96866 MW;  611F18831F42A6AD CRC64;
     MNQEVKNKIF SILKITFATA LFIFVAITLY RELSGINFKD TLVEFSKINR MSLVLLFIGG
     GASLVILSMY DVILSRALKM DISLGKVLRV SYIINALNAI VGFGGFIGAG VRAMVYKNYT
     HDKKKLVHFI SLILISMLTG LSLLSLLIVF HVFDASLILD KITWVRWVLY VVSFFLPLFI
     IYSMVRPPDK NNRFVGLYCT LVSCVEWLAA AVVLYFCGVI VDAHVSFMSF IAIFIIAALS
     GLVSFIPGGF GAFDLVVLLG FKTLGVPEEK VLLMLLLYRF AYYFVPVIIA LILSSFEFGT
     SAKKYIEGSK YFIPAKDVTS FLMSYQKDII AKIPSLSLAI LVFFTSMIFF VNNLTIVYDA
     LYDGNHLTYY ILLAIHTSAC LLLLLNVVGI YKQSRRAIIF AMISILLITV ATFFTYASYI
     LITWLAIIFV LLIVAFRRAR RLKRPVRMRN IVAMLLFSLF ILYVNHIFIA GTLYALDIYT
     IEMHTSVLRY YFWLTILIIA IIIGMIAWLF DYQFSKVRIS SKIEDCEEII NQYGGNYLSH
     LIYSGDKQFF TNENKTAFLM YRYKASSLVV LGDPLGDENA FDELLEAFYN YAEYLGYDVI
     FYQVTDQHMP LYHNFGNQFF KLGEEAIIDL TQFSTSGKKR RGFRATLNKF DELNISFEII
     EPPFSTEFIN ELQHVSDLWL DNRQEMHFSV GEFNEEYLSK APIGVMRNEE NEVIAFCSLM
     PTYFNDAISV DLIRWLPELD LPLMDGLYLH MLLWSKEQGY TKFNMGMATL SNVGQLHYSY
     LRERLAGRVF EHFNGLYRFQ GLRRYKSKYN PNWEPRFLVY RKDNSLWESL SKVMRVIRHK
//
